

CURRICULUM VITAE
LANFRANCO CALLEGARO

PERSONAL PARTICULARS:

| | |
|-----------------------------------|---|
| <i>Name:</i> | Lanfranco Callegaro |
| <i>Date & Place of Birth:</i> | 23/06/1951 – Noventa Padovana (PD), Italy |
| <i>Marital Status:</i> | Married; 2 children |
| <i>Citizenship:</i> | Italian |

EDUCATION:

| | |
|------|---|
| 1970 | Graduated from High School |
| 1975 | PhD in Chemical Sciences, University of Padua |

PRESENT POSITION:

| | |
|----------------|---|
| 2001 – present | Chief Operating Officer, Fidia Farmaceutici SpA |
|----------------|---|

PROFESSIONAL APPOINTMENTS:

| | |
|----------------|--|
| 1976 – 1979 | Postdoctoral Fellow, Protein Chemistry, Biopolymers Center, National Research Council, University of Padua |
| 1979 – 1984 | Senior Researcher, Biomedical Department, Sorin Biomedica, Saluggia (VC), Italy |
| 1984 – 1986 | Director, Immunodiagnostic Research and Development, Sorin Biomedica, Saluggia (VC), Italy |
| 1986 – 1989 | Head, Molecular Biochemistry Department, Fidia SpA, Abano Terme (PD), Italy |
| 1989 – 1992 | Head, Advanced Technology Division, Fidia SpA., Abano Terme (PD), Italy |
| 1992 – 1994 | Founder and Managing Director, Fidia Advanced Biopolymers Srl (Fidia Group), Abano Terme (PD), Italy |
| 1994 – 2001 | Director, Corporate Development, Fidia SpA, Abano Terme (PD), Italy |
| 1994 – present | Chief Executive Officer, Fidia Advanced Biopolymers Srl |
| 2001 - present | Chief Operating Officer, Fidia Farmaceutici SpA, Abano Terme |

| | |
|-----------------|--|
| <i>PATENTS:</i> | Author and/or co-author of more than 60 patents, filed in countries throughout the world |
|-----------------|--|

MAJOR INDUSTRIAL PERFORMANCES

| | |
|----------------|---|
| 1979 – 1986 | <u>Sorin Biomedica SpA, Saluggia (VC), Italy</u> Development of hollow fibre enzymatic bioreactors for liver detoxification Development and commercialization of a full line ELISA diagnostic assays for the determination of hepatitis and oncological markers Biochemical and clinical development of three radiotracers using monoclonal antibodies for the in- vivo detection of tumour masses |
| 1986 – 1989 | <u>Fidia SpA</u> Cloning and expression of growth factors for nerve, skin and bone regeneration |
| 1994 – 1996 | <u>Fidia SpA</u> Development of the strategy and the organization of HYALGAN registration in USA with worldwide management teams |
| 1996 – 1999 | <u>Fidia SpA</u> Responsible for the development of new business and products using Hyaluronic acid and its derivate |
| 1999 – 2001 | <u>Fidia SpA</u> Member of the steering committee for the analyses and the strategic development of new pharmaceutical business of the company |
| 2001 – 2003 | <u>Fidia Farmaceutici SpA</u> Responsible for domestic sales |
| 2003 – present | <u>Fidia Farmaceutici SpA</u> Chief Operating Officer of the company (e.g. domestic and international sales, production, R&D and registration field) |
| 1992 – present | Founder of the biotech company, <u>Fidia Advanced Biopolymers (FAB)</u> which is focused on the development, production and commercialization of innovative biomaterials and Tissue Engineered products At present FAB is one of the leading companies at international level in the R&D and Commercialization of Tissue Engineering products and innovative biomaterials based on the new hyaluronic acid technologies. It was sold to Anika Therapeutics Inc. in 2009 |